CCND1 and benign prostatic hyperplasia: Oral administration of PA (100 mg/kg/day for 4 weeks) can reduce the expression levels of AR, 5ar2, PSA, PCNA, cyclin D1, Bcl-2 in prostate tissue and serum DHT level, ultimately improving prostate weight in rats with BPH (127).